Athira Pharma Inc ATHA.OQ ATHA.O is expected to show no change in quarterly revenue when it reports results on July 30 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Athira Pharma Inc is for a loss of 18 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Athira Pharma Inc is $0.40, about 14.5% below its last closing price of $0.46
This summary was machine generated July 28 at 11:13 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)